Doxorubicin (DOX) has aroused contradiction between its potent antiâtumor capacity and severe cardiotoxicity. Galangin (Gal) possesses antioxidant, antiâinflammatory, and antiapoptotic activities. We aimed to explore the role and underlying mechanisms of Gal on DOXâinduced cardiotoxicity. Mice were intraperitoneally injected with DOX (3âmg/kg, every 2âdays for 2âweeks) to generate cardiotoxicity model and Gal (15âmg/kg, 2âweeks) was coâadministered via gavage daily. Nuclear factor erythroid 2ârelated factor 2 (Nrf2) specific inhibitor, ML385, was employed to explore the underlying mechanisms. Compared to DOXâinsulted mice, Gal effectively improved cardiac dysfunction and ameliorated myocardial damage. DOXâinduced increase of reactive oxygen species, malondialdehyde, and NADPH oxidase activity and downregulation of superoxide dismutase (SOD) activity were blunted by Gal. Gal also markedly blocked increase of ILâ1ÎČ, ILâ6, and TNFâα in DOXâinsulted heart. Mechanistically, Gal reversed DOXâinduced downregulation of Nrf2, HOâ1, and promoted nuclear translocation of Nrf2. ML385 markedly blunted the cardioprotective effects of Gal, as well as inhibitive effects on oxidative stress and inflammation. Gal ameliorates DOXâinduced cardiotoxicity by suppressing oxidative stress and inflammation via activating Nrf2/HOâ1 signaling pathway. Gal may serve as a promising cardioprotective agent for DOXâinduced cardiotoxicity.